"Despite the cell and gene therapy (CGT) space experiencing a notable funding slump, some investors were encouraged over the past few months to reexamine this trend."
https://www.pharmamanufacturing.com/development/article/55252426/how-dealmaking-may-jumpstart-cgt-development-again?o_eid=5174I8714801J9J&oly_enc_id=5174I8714801J9J&rdx.ident[pull]=omeda|5174I8714801J9J&utm_campaign=CPS250102033&utm_medium=email&utm_source=PHAR+Daily+Dose
No comments:
Post a Comment